All Clinical Resources

1 - 12 of 13 results

This podcast episode considers recent data that sheds light on how diet soda and artificial sweeteners might influence CNS outcomes, especially the risk for ischemic stroke.


Teaching patients lifestyle management strategies to improve health is no easy task. First steps involve increasing provider knowledge of the impact foods have on health. This episode discusses the latest evidence on different types of meat intake and meat associated compounds on health.


Oxygen is frequently given to patients routinely during the initial treatment of a myocardial infarction, but there is a lack of data to support or refute this. A recent systematic review found no benefit in patients who did not have baseline hypoxia. Oxygen therapy continues to be indicated for those with hypoxia and needs to be used with caution in COPD patients with carbon dioxide retention


In this podcast episode, we will talk about how systolic hypertension affects outcomes, put into context a recent JACC systematic review paper on the topic and JNC 8. We will also discuss the Number Needed to Treat (NNT) and the Number Needed to Harm (NNH).


In this podcast episode, we will consider the rationale for using non-fasting labs to screen for ASCVD as well as review the controversies around their use and talk about the differential diagnosis of hypertriglyceridemia.


Join us as we examine the risk of hospitalization for heart failure (HF) among patients with type 2 diabetes (T2D) and explore evidence-based risk reduction strategies that you can incorporate into your practice. We will discuss the results of the DECLARE trial, the largest cardiovascular (CV) outcomes trial to study hospitalization for HF reduction in patients with T2D and established CV disease or multiple CV risk factors. We'll also discuss the results of the landmark DAPA-HF trial that support FARXIGA being the FIRST and ONLY FDA-approved sodium-glucose cotransporter 2 inhibitor (SGLT2) for patients with HF with reduced ejection fraction (HFrEF) with and without T2D.


Although heart failure contributes to millions of hospitalizations in the United States each year that significantly impact patient prognosis, treatment is often focused on managing symptoms rather than on optimizing therapy.1,2 In this episode, featuring cardiologist Dr Javed Butler of the University of Mississippi, we will discuss best practices for navigating a heart failure hospitalization, including assessment of the patient’s clinical trajectory and optimization of guideline-directed medical therapy.


The clinical course of heart failure is punctuated by multiple episodes of hospitalization,1-3 leading to poor outcomes and high and escalating costs.4,5 This highlights the need to reimagine how heart failure care is delivered. In this episode, featuring Dr Nihar Desai of the Yale School of Medicine, we will explore the interplay between implementing quality improvement initiatives, specifically value-based care models, and optimizing heart failure care.


Although heart failure with preserved ejection fraction (HFpEF) is common and increasing in prevalence, persistent misconceptions, including a perceived lack of therapeutic options, limit its effective management.1,2 In this episode, featuring cardiologist Dr. John Ryan of the University of Utah, we will counteract these misconceptions through exploration of various HFpEF patient profiles, covering key aspects of HFpEF diagnosis and optimal management in inpatient and outpatient settings.


The clinical course of heart failure is progressive and often involves periods of disease worsening that can be challenging to identify for both patients and their health care providers.1-4 In this episode, featuring cardiologist Dr Lee Goldberg of the University of Pennsylvania, we will discuss key aspects of the clinical assessment of heart failure worsening and progression in the outpatient setting and emphasize the importance of optimizing guideline-directed medical therapy in patients with worsening heart failure as well as in those with stable disease.


This program will highlight a different approach to the treatment of heart failure with reduced ejection fraction (HFrEF). By targeting a mechanism of action aligned to pathophysiologic pathways, it is possible to reduce patient mortality and morbidity, while providing a proven safety and tolerability profile to help provide confidence in selecting your first-choice therapy for patients with HFrEF.